Cure8 news brief
These patient-derived human tissue models aim to let drug developers test whether a candidate affects disease-relevant biology in human intestinal tissue before moving to clinical trials, which could help reduce failures for lack of efficacy.
For people with Crohn’s or ulcerative colitis, better preclinical human models could speed development of therapies that actually work in patients.
Researchers and drug developers working on IBD; clinicians following experimental therapies; adult patients and caregivers interested in progress in IBD drug discovery and translational models.
VivoSim announced expansion of its NAMkind™ human tissue platform to include disease-focused liver (MASH) and intestinal (IBD) models built from patient-derived cells, with the intestine models derived from donors with ulcerative colitis and Crohn’s disease.
The platform measures functional endpoints (barrier integrity, inflammation, fibrosis) alongside biomarker panels and runs test compounds in donor-matched tissue with clinically used reference drugs (examples cited include tofacitinib, upadacitinib, and methotrexate).
The company positions these models for preclinical efficacy testing and mechanistic biomarker profiling to help drug developers assess likely human efficacy before clinical trials.
This is a company press release describing commercial service expansion and internally published/posted results and posters. It is not a peer-reviewed clinical trial report; claims about model performance are based on company-published data and conference abstracts/posters.
The platform uses donor-derived tissues and reports donor-by-donor readouts, which may help capture human heterogeneity but does not substitute for clinical trial evidence of patient benefit.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
